Kura Oncology KURA

$7.57 +0.30 (4.13%)

Valuation

Market cap
646,746,000
Revenue TTM
$67,480,000
Net income TTM
$-278,670,000
P/E (trailing)
0.00
P/E (forward)
—
Profit margin
-412.97%
Debt to equity
0.20

Trading

Volume
2,101,400
Avg volume
1,930,148
Day's range
$7.07 – $7.76
Shares out
88,961,000
Stochastic %K
20%
Beta
0.56
Analysts
Strong Buy
Price target
$31.54

Price

Company profile

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tum...

Show more

Kura Oncology, Inc., a clinical-stage biopharmaceutical company, develops medicines for the treatment of cancer. The company's first commercial product, KOMZIFTI (ziftomenib), a potent, selective, reversible and oral small molecule menin inhibitor; Darlifarnib, a Phase 1 first-in-human FIT-001 trial which includes multiple cohorts to evaluate darlifarnib in combination with other targeted therapies in large solid tumor indications; and KO-7246, a next-generation menin inhibitor, for use in diabetes and cardiometabolic disorders and additional next-generation menin inhibitors for use in combination with other therapies in solid tumors. The company is headquartered in San Diego, California.

Industry
Biotechnology
Sector
Healthcare
Phone
858 500 8800
Website
https://www.kuraoncology.com
Address
4930 Directors Place, Suite 500, San Diego, United States

Latest news

Stocktwits

beachsidefreddy Nov 10, 2:33 PM
$KURA nothing real till 10 am
0 replies
beachsidefreddy Nov 10, 2:21 PM
$KURA lets run these buy in order so everyone has all knowledge. 1) CEO spends $2.3 mill of his own money to buy 200,000 in open market at $12.39.................. NOT CO. AWARDED 2) Nov 2 Co. buys stock for non mgmnt hires(good thing hires) at $7.97 3)J&J trial found to be swiss cheese and stock starts recovery as it should 4) Q3 today at 4 with CC to follow. 5)CEO IS NOT INSANE!!
1 replies
beachsidefreddy Nov 10, 1:54 PM
$KURA PROOF: 36 minutes ago 2026-11-10 13:16:29.2 6,200,000 AVAILABLE HAS BEEN 3.5 MILL
0 replies
beachsidefreddy Nov 10, 1:39 PM
$KURA shorts just RETURNED all they can(fact)!!!!!! dont want to play a stock going up 2 points today!!! lol
0 replies
Kai_01 Nov 10, 11:32 AM
$KURA Some key facts to be aware of. Still early days in DD but so far looking extraordinary. 1. FDA approved, at ultra speed, which is often a good sign. 2. Undervalued (rNPV is $9.40) 3. EV is small relative to its cash; extremely strong funding structure. 4. 88.96M outstanding shares (in case you were also in IOVA, for reference, IOVA has 400M!) 5. A one-day pill, no cell therapy and so on related complexity and challenges 6. Extraordinary commentary from doctors hinting at a potential high penetration rate and high-quality clinical trial design and data 7. Strong and full calendar catalyst (see image with black background attached). No binary event until 2028 (always peaceful, although of course there's potential for upside and downside) 8. Buy out setup; potentially by one of its partners (Kyowa Kirin) 9. CEO bought 100,000 shares for about $1.24 million a few months ago 10. Price targets by analysts (never to use as a key investment variable but good nonetheless).
1 replies
shoc24 Nov 10, 5:48 AM
$KURA reports earnings tomorrow after the close. I used Stock Meadow's earnings dashboard to review its history: KURA has beaten EPS estimates in 4 of its last 8 reports.
0 replies
rabbitsoup Nov 10, 5:34 AM
$SNDX Earnings, abstracts and conference dates have been released. Unless I don't understand the window-Any and all insiders should be able to buy stock NOW in the open market with their own $. You would think-they would be jumping at this opportunity to buy cheap stock.. If they're allowed to buy, and don't think the stock is way oversold and worth purchasing at this price/valuation w upcoming milestones- they should not receive any shares (RSUs) rewards etc. A real leader/$KURA CEO recently purchased approx. $2MM of his stock in the open market at higher prices. If there are no$SNDX purchases -it shows-mngmt. is sleazy and not aligned at all with their shareholders. The $SNDX BOD have been treated with kid gloves and (no accountability) BOD need to respond directly to shareholders about the current stock price and multi-year-non-stop losses and how they dare justify handing out more free shares to executive losers while nobody is willing to purchase with their own $.
0 replies
TradingLittlePharma Nov 10, 12:14 AM
$CPA will probably continue to climb after earnings, investors should expect tighter margins due to higher fuel prices and take that into account but we'll see. $KURA we're going up after earnings, I know it. $NU will rally back toward 16 after the overreaction due to the election in Brazil. $GRAB is losing steam, so I'm looking for a bull flag to start forming over the next 2 or 3 days. Lastly, $URGN is going to back up, easy peazy.
0 replies